nitazoxanide has been researched along with zithromax in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 8 (47.06) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Barchiesi, F; Burzacchini, F; Cirioni, O; Dini, M; Giacometti, A; Scalise, G | 1 |
| Ancarani, F; Barchiesi, F; Cirioni, O; Giacometti, A; Scalise, G | 1 |
| Cabada, MM; Pantenburg, B; White, AC | 1 |
| Rossignol, JF | 1 |
| Dalle, F; Deconinck, E; Grenouillet, F; Larosa, F; Legrand, F; Millon, L; Rohrlich, PS; Saas, P | 1 |
| Beamer, G; Campbell, MA; Girouard, D; Harwood, M; Lee, S; Meyers, MJ; Tzipori, S | 1 |
| DeBoer, MD; Donowitz, JR; Gratz, J; Houpt, ER; Jatosh, S; McDermid, JM; Mduma, E; Platts-Mills, JA; Scharf, RJ; Svensen, E; Swann, JR; Wanjuhi, AW | 1 |
| Kelleni, MT | 2 |
| DeBoer, MD; Donowitz, JR; Elwood, SE; Gratz, J; Houpt, ER; Jatosh, S; Katengu, S; Kivuyo, S; McDermid, JM; Mdoe, P; Mduma, E; Parpia, TC; Platts-Mills, JA; Rogawski McQuade, ET; Scharf, RJ; Svensen, E; Swann, JR; Wanjuhi, AW | 2 |
| Bayo, E; Blacy, L; DeBoer, M; Elwood, S; Houpt, E; Mduma, E; Parpia, T; Platts-Mills, J; Rogawski McQuade, E; Scharf, R; Svensen, E; Wanjuhi, A | 1 |
| Muñoz-Cordero, B; Romero-Cabello, R; Romero-Feregrino, R; Sevilla-Fuentes, S | 1 |
2 review(s) available for nitazoxanide and zithromax
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment of cryptosporidiosis.
Topics: AIDS-Related Opportunistic Infections; Animals; Antiretroviral Therapy, Highly Active; Azithromycin; Biliary Tract Diseases; Coccidiostats; Cryptosporidiosis; Humans; Immunocompromised Host; Nitro Compounds; Paromomycin; Rifamycins; Rifaximin; Thiazoles | 2009 |
4 trial(s) available for nitazoxanide and zithromax
| Article | Year |
|---|---|
Early Life Interventions for Childhood Growth and Development in Tanzania (ELICIT): a protocol for a randomised factorial, double-blind, placebo-controlled trial of azithromycin, nitazoxanide and nicotinamide.
Topics: Administration, Oral; Anti-Bacterial Agents; Antiparasitic Agents; Azithromycin; Breast Feeding; Double-Blind Method; Female; Growth and Development; Humans; Infant; Infant, Newborn; Male; Mothers; Niacinamide; Nitro Compounds; Randomized Controlled Trials as Topic; Tanzania; Thiazoles; Vitamin B Complex | 2018 |
Baseline Characteristics of Study Participants in the Early Life Interventions for Childhood Growth and Development in Tanzania (ELICIT) Trial.
Topics: Adult; Azithromycin; Body Weight; Child Health; Child Nutrition Disorders; Child, Preschool; Cohort Studies; Early Medical Intervention; Female; Humans; Infant; Infant, Newborn; Male; Mothers; Neonatal Sepsis; Niacinamide; Nitro Compounds; Poverty; Respiratory Tract Infections; Rural Population; Seasons; Surveys and Questionnaires; Tanzania; Thiazoles; Young Adult | 2020 |
Effect of scheduled antimicrobial and nicotinamide treatment on linear growth in children in rural Tanzania: A factorial randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anti-Infective Agents; Azithromycin; Child Development; Double-Blind Method; Drug Administration Schedule; Female; Growth Disorders; Humans; Infant; Infant, Newborn; Intestinal Diseases, Parasitic; Niacinamide; Nitro Compounds; Pregnancy; Tanzania; Thiazoles | 2021 |
Cognitive Outcomes at 18 Months: Findings from the Early Life Interventions for Childhood Growth and Development in Tanzania (ELICIT) Trial.
Topics: Anti-Infective Agents; Antiparasitic Agents; Azithromycin; Child Development; Cognitive Aging; Cohort Studies; Early Intervention, Educational; Female; Humans; Infant; Male; Niacinamide; Nitro Compounds; Seasons; Tanzania; Thiazoles; Vitamin B Complex | 2021 |
11 other study(ies) available for nitazoxanide and zithromax
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Azithromycin; Cryptosporidiosis; Cryptosporidium; Drug Therapy, Combination; Feces; Female; Humans; Nitro Compounds; Paromomycin; Thiazoles; Treatment Outcome | 1999 |
Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture.
Topics: AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cell Survival; Cells, Cultured; Cryptosporidiosis; Cryptosporidium parvum; Humans; Nitro Compounds; Rifabutin; Thiazoles | 2000 |
Cryptosporidium and Giardia: treatment options and prospects for new drugs.
Topics: AIDS-Related Opportunistic Infections; Antibodies, Monoclonal; Antiparasitic Agents; Antiretroviral Therapy, Highly Active; Azithromycin; Benzimidazoles; Cryptosporidiosis; Giardia lamblia; Giardiasis; Humans; Nitro Compounds; Nitroimidazoles; Paromomycin; Roxithromycin; Thiazoles | 2010 |
Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study.
Topics: Adult; Animals; Azithromycin; Cryptosporidiosis; Cryptosporidium parvum; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Lymphopenia; Male; Middle Aged; Nitro Compounds; Thiazoles; Transplantation, Homologous; Young Adult | 2011 |
The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominis.
Topics: Animals; Animals, Newborn; Anti-Bacterial Agents; Antiparasitic Agents; Azithromycin; Cryptosporidiosis; Cryptosporidium; Disease Models, Animal; Drug Therapy, Combination; Nitro Compounds; Sus scrofa; Swine; Thiazoles; Treatment Outcome | 2017 |
Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management.
Topics: Antiparasitic Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Humans; Nitro Compounds; Pandemics; Pneumonia, Viral; SARS-CoV-2; Thiazoles | 2020 |
NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Repositioning; Humans; Interferons; Interleukin-6; Nitro Compounds; Observational Studies as Topic; SARS-CoV-2; Thiazoles | 2022 |
Outpatient treatment of COVID-19: an experience with 552 cases in Mexico.
Topics: Azithromycin; COVID-19; Humans; Mexico; Outpatients; Prednisone; SARS-CoV-2; Treatment Outcome | 2023 |